C12-200 is a cationic lipid for Lipid NanoParticles as delivery systems for enabling the therapeutic potential of siRNA, mRNA or CRISPR as they exhibit remarkable in vivo potencies at low doses.C12-200 is a common positive control ionizable lipid for
exploring new ionizable lipids. C12-200 is an ionizable
lipid with five tails. The tri-palmitoyl-Sglyceryl
cysteine linked to the pentapeptide (Pam3)-modified C12-200 iLNPs was developed to deliver tumor antigen mRNA
for enhancing the mRNA-mediated cancer immunotherapy.
The results of the therapeutic evaluation showed that Pam3-
modified C12-200 iLNPs could almost inhibit tumor growth in
tumor-bearing mice. To improve delivery efficiency, the
formulation was optimized to replace the phospholipids from
DSPC to DOPE, and the result showed that optimized
formulation induced EPO protein expression was seven times
that of the initial formulation,[35] and the formulation has been
used in the study for mRNA-mediated human α-galactosidase
protein replacement therapy in mice and nonhuman
primates.
Cat.No
DC58046
Name
C12-200
Chemical Properties
CAS
1220890-25-4
Formula
C70N5O5H145
MW
1136.931
Storage
pure form: -20°C/3 years,4°C/2 years; In solvent: -20°C/1 month
References
1. Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes,
J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky,
Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin de Fougerolles, Kevin Fitzgerald, Victor Koteliansky,
Akin Akinc, Robert Langer, Daniel G. Anderson, Proceedings of the National
Academy of Sciences, Feb 2010, 107 (5) 1864-1869; DOI: 10.1073/pnas.0910603106
2. Leuschner F, Courties G, Dutta P, Mortensen LJ, Gorbatov R, Sena B, Novobrantseva T, Borodovsky A,
Fitzgerald K, Koteliansky V, Iwamoto Y, Bohlender M, Meyer S, Lasitschka F, Meder B, Katus HA, Lin C,
Libby P, Swirski FK, Anderson DG, Weissleder R, Nahrendorf M. Eur Heart J.
2015 Jun 14;36(23):1478-88. doi: 10.1093/eurheartj/ehu225. Epub 2014 Jun 20.
3. Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW1, DeRosa F1, Mir FF, Fenton OS, Anderson DG. Nano Lett.
2015 Nov 11;15(11):7300-6. doi: 10.1021/acs.nanolett.5b02497. Epub 2015 Oct 20.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
